Angola vs Indonesia: HIV/AIDS deaths averted by antiretroviral therapy
Angola
14,494 deaths
in 2024
Indonesia
14,389 deaths
in 2024
Angola rank
16th
Indonesia rank
17th
HIV/AIDS deaths averted by antiretroviral therapy over time
- Angola
- Indonesia
How they compare
Angola currently reports 14,494 deaths against 14,389 deaths in Indonesia, a difference of 105 deaths.
The two have swapped places 5 times across 35 shared years of data; in 1990 it was Indonesia ahead.
Angola ranks 16th and Indonesia ranks 17th of 157 countries.
Angola has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Angola | Indonesia | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | -0.0142 deaths | 0.0142 deaths | Angola |
| 2000s | 765.87 deaths | 655.3 deaths | 110.57 deaths | Angola |
| 2010s | 7,024 deaths | 6,279 deaths | 745.44 deaths | Angola |
| 2020s | 12,363 deaths | 12,043 deaths | 320.11 deaths | Angola |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Angola or Indonesia?
- Angola, at 14,494 deaths against 14,389 deaths in Indonesia as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Angola and Indonesia?
- 105 deaths, with Angola ahead.
- How many years of comparable data are there for Angola and Indonesia?
- 35 years are reported by both, from 1990 to 2024.
- How do Angola and Indonesia rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Angola ranks 16th and Indonesia ranks 17th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.